Resolution of Myelofibrosis-Associated Pulmonary Arterial Hypertension following Allogeneic Hematopoietic Stem Cell Transplantation. (December 2016)

• Record Type: Journal Article
• Authors: Faiz, Saadia A.; Iliescu, Cezar; Lopez-Mattei, Juan; Patel, Bela; Bashoura, Lara; Popat, Uday
• Is Part Of: Pulmonary circulation. Volume 6:Number 4(2016)
• Page Start: 611
• Page End: 613
• Publication Date: 2016-12
• Subjects: pulmonary arterial hypertension -- hematopoietic stem cell transplantation -- myeloproliferative disease -- myelofibrosis -- cancer -- pulmonary vascular disease; Pulmonary circulation -- Periodicals; Pulmonary circulation; Electronic journals -- Sciences; Periodicals; 616.24005
• DOI: 10.1086/687291
• Languages: English
• ISSNs: 2045-8932

Abstract

We present the case of a 62-year-old man with myelofibrosis-associated pulmonary arterial hypertension (PAH) who underwent allogeneic hematopoietic stem cell transplantation with subsequent resolution of disease and PAH. Right heart catheterization was used to guide PAH therapy before and after transplantation. Drug interactions, adverse effects, and renal insufficiency posed clinical challenges for the management of PAH-specific medications after transplantation. PAH improved soon after transplantation, and vasoactive medications were tapered off. Resolution of PAH was confirmed with repeat measurement of pulmonary hemodynamic characteristics. Although the etiology and pathophysiology for the resolution of PAH was unclear, the myelopulmonary pathophysiologic link was likely to have contributed. This is the first report describing resolution of myelofibrosis-associated PAH after allogeneic hematopoietic stem cell transplantation.